NexImmune Stock Forecast, Price & News

+0.89 (+4.99 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $18.74
50-Day Range
MA: $21.40
52-Week Range
Now: $18.74
Volume13,483 shs
Average Volume140,141 shs
Market Capitalization$426.48 million
P/E RatioN/A
Dividend YieldN/A
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.
NexImmune logo

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:NEXI
Phone301 825 9810
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$426.48 million
Next Earnings Date6/30/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

2.03 out of 5 stars

Medical Sector

51st out of 2,016 stocks

Biotechnology Industry

4th out of 144 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.89 (+4.99 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NEXI News and Ratings via Email

Sign-up to receive the latest news and ratings for NEXI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

NexImmune (NASDAQ:NEXI) Frequently Asked Questions

Is NexImmune a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NexImmune in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NexImmune stock.
View analyst ratings for NexImmune
or view top-rated stocks.

What stocks does MarketBeat like better than NexImmune?

Wall Street analysts have given NexImmune a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NexImmune wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is NexImmune's next earnings date?

NexImmune is scheduled to release its next quarterly earnings announcement on Wednesday, June 30th 2021.
View our earnings forecast for NexImmune

What price target have analysts set for NEXI?

3 analysts have issued 1-year price targets for NexImmune's stock. Their forecasts range from $30.00 to $35.00. On average, they anticipate NexImmune's stock price to reach $33.33 in the next year. This suggests a possible upside of 77.9% from the stock's current price.
View analysts' price targets for NexImmune
or view top-rated stocks among Wall Street analysts.

Who are NexImmune's key executives?

NexImmune's management team includes the following people:
  • Mr. Scott P. Carmer, Pres, CEO & Director (Age 56, Pay $518.36k)
  • Mr. John Trainer M.B.A., Chief Financial Officer (Age 47, Pay $342.44k)
  • Ms. Kristi Jones, Chief Operating Officer (Age 58, Pay $397.48k)
  • Dr. Mathias Oelke, Sr. VP of Preclinical Immunotherapy & Head of Cell Biology
  • Dr. Daniel P. Bednarik, Sr. VP of Molecular Engineering & Protein Design
  • Dr. Jerome Bernard Zeldis, Exec. VP of R&D (Age 71)
  • Dr. Robert Douglas Knight M.D., Chief Medical Officer (Age 70)

Who are some of NexImmune's key competitors?

When did NexImmune IPO?

(NEXI) raised $75 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. acted as the underwriters for the IPO.

What is NexImmune's stock symbol?

NexImmune trades on the NASDAQ under the ticker symbol "NEXI."

When does the company's lock-up period expire?

NexImmune's lock-up period expires on Wednesday, August 11th. NexImmune had issued 6,471,000 shares in its public offering on February 12th. The total size of the offering was $110,007,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of NexImmune?

Shares of NEXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NexImmune's stock price today?

One share of NEXI stock can currently be purchased for approximately $18.74.

How much money does NexImmune make?

NexImmune has a market capitalization of $426.48 million.

What is NexImmune's official website?

The official website for NexImmune is

How can I contact NexImmune?

The company can be reached via phone at 301 825 9810.

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.